JUBLINGREA - Jubilant Ingrevia Limited Share Price

Management's outlook for Jubilant Ingrevia Limited is optimistic, primarily driven by continued growth in the Specialty Chemicals and Nutrition segments, and a partial recovery in the acetyls portfolio. They anticipate sustained growth momentum, underpinned by operational efficiency enhancements following the commissioning of a new boiler at the Bharuch site.

Key forward-looking points include:

1. Volume and Revenue Growth: The management projects revenue growth driven by double-digit volume increases. During Q4 FY '26, they expect to capitalize on several confirmed orders, particularly in the CDMO (Contract Development and Manufacturing Organization) segment.

2. New Contracts and Capex Investments: Significant milestones are anticipated with the delivery of a major CDMO order in Q4 FY '26. Construction on a new multipurpose plant in Gajraula has also commenced, aimed at bolstering their capacity for CDMO projects.

3. Financial Expectations: For the nine months ended December 31, 2025, revenue increased by 3%, while EBITDA rose by 8%. Management is excited for continued growth trajectory, targeting expansion aided by recent FTAs signed with the US and EU, enhancing engagement opportunities with customers.

4. Operational Efficiency Goals: The company aims to sustain an overall EBITDA margin at 13% and target lean savings of over INR 120 crore annually, reinforcing their efficiency amidst exceptional expense adjustments related to new labor code amendments.

5. Dividend Declaration: The board recommended an interim dividend of 250%, translating to INR 2.5 per share, reflecting confidence in future profitability.

6. Strategy and Pipeline Expansion: Management highlighted ongoing advancements in their product pipeline, noting an opportunity funnel of over 100 active prospects with a potential peak revenue of INR 3,500 crore, signaling robust future growth potential.

In summary, Jubilant Ingrevia's management appears confident in their ability to navigate current market pressures and leverage new growth opportunities, projecting a stable and growing financial outlook in the near future.

Major Questions Asked in Q&A and Their Detailed Answers

1. Question: "Is the continuous pricing pressure supposed to be seen as price decline happening quarter after quarter sequentially? How transient would it be in your opinion, specifically for pyridine, B3, and acetyls?"

Answer: Pricing pressures have been observed particularly in the specialty chemicals segment like pyridine. However, we are already seeing some uptick in pricing for certain derivatives. For vitamin B3, there's been a recent 7-8% price increase, expected to be sustainable. Acetyl prices have bottomed out, and we are anticipating a turnaround as acetic acid prices improve, indicating a potential upward trend in all product categories.

2. Question: "On the previous quarterly call, we had mentioned around INR1,200 crore for the net realizable value of products, which has now increased to INR1,400 crore. Can you provide insights into the timeline for realizing this benefit, specifically how it relates to CDMO initiatives?"

Answer: Our pipeline consists of over 100 opportunities with a peak potential revenue of INR3,500 crore. Typically, it takes 3-4 years to reach peak demand. The increase to INR1,400 crore signifies growth, with 16 confirmed molecules contributing to our revenue this fiscal year, particularly in the CDMO segment, where we anticipate a notable jump in revenues coming in FY '27.

3. Question: "For the agrochemical intermediate project, can you specify if we expect meaningful business in fiscal '26, and how quickly will it scale up to its full potential in '27?"

Answer: We are on track to begin adding output from the new agrochemical project in March 2026. Initially, we'll aim to maximize production within this quarter. We anticipate growth will depend on customer visibility, but we expect significant scaling to occur in the fiscal year '27 with full production potential realized shortly thereafter.

4. Question: "What is your outlook for fiscal '27, considering the recent pricing pressures and overall business performance?"

Answer: While it may be early to provide definitive guidance for fiscal '27, our expectation is to maintain growth with a target EBITDA growth of at least 20% CAGR over the next several years. Moreover, the pricing situation appears to be stabilizing, which should positively impact our quarterly performance.

5. Question: "Can you provide some clarity on the CDMO arrangement and how customer commitments might insulate us against market pressures, specifically regarding volume risks?"

Answer: We have contractual agreements with our CDMO customers to ensure minimum volume commitments, shielding us from potential risks due to market volatility. Our portfolio's diversity allows us to manage these commitments effectively without significant exposure to any single market risk.

6. Question: "Regarding the FTAs with the U.S. and EU, which products do you expect to gain market share, and how will that affect volumes and pricing going forward?"

Answer: The U.S. FTA mainly affects products that constituted about 2% of our portfolio. However, the EU FTA will remove a 6-7% tariff on several products, enabling greater competitiveness and likely increasing volumes. We have already seen rising shares in products like choline as favorable tariffs come into effect, signaling expected growth in these markets.

7. Question: "As for the profitability of your large agrochemical CDMO order, can you clarify the expected margins and how they compare to industry standards?"

Answer: While I can't disclose exact margins, we maintain a threshold margin of 20% EBITDA for all projects. The agro segment typically sees margins between 20% and 25%, which aligns well with industry standards, and we view this collaboration as mutually beneficial for maintaining competitiveness.

These answers encapsulate the key points discussed during the Q&A while adhering to the requested character limit and completeness in response.